This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PRTG Portage Biotech (PRTG) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Portage Biotech Stock (NASDAQ:PRTG) Get Portage Biotech alerts:Sign Up Key Stats Today's Range$6.80▼$9.4350-Day Range$6.81▼$9.9752-Week Range$5.23▼$12.24Volume377,941 shsAverage Volume194,833 shsMarket Capitalization$8.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Portage Biotech Inc. (NASDAQ: PRTG) is a clinical‐stage biotechnology company focused on building a diversified portfolio of innovative therapeutics targeting rare diseases and oncology indications. Leveraging an asset‐centric business model, Portage Biotech acquires and in‐licenses development‐stage compounds from academic institutions and biotechnology partners, then advances these assets through preclinical studies and early‐stage clinical trials within dedicated subsidiary entities. The company’s pipeline spans small molecules, biologics and cell therapies, with programs directed at conditions such as myeloproliferative disorders, inherited blood disorders and solid tumor oncology. By organizing each development program under a stand‐alone subsidiary, Portage Biotech centralizes shared functions—such as regulatory affairs, manufacturing and clinical operations—while allowing focused teams to drive individual assets toward key value‐creating milestones. Headquartered in New York, Portage Biotech maintains collaborations with research institutions in North America and Europe to expand its discovery footprint and accelerate candidate selection. The company’s management team brings experience from established biopharmaceutical and venture‐backed organizations, supporting a strategy of disciplined capital allocation and milestone‐driven advancement. Portage Biotech’s approach aims to unlock value in early‐stage projects through targeted partnerships and efficient resource deployment, positioning the company to out‐license or co‐develop programs as they progress toward pivotal clinical readouts.AI Generated. May Contain Errors. Read More Receive PRTG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRTG Stock News HeadlinesTON holds steady as AlphaTON Capital unveils $100 million Toncoin treasury planSeptember 5, 2025 | fxstreet.comPortage Biotech, renamed AlphaTON Capital, launches TON digital asset treasurySeptember 3, 2025 | msn.comSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page.June 25 at 1:00 AM | Weiss Ratings (Ad)AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram EcosystemSeptember 3, 2025 | globenewswire.comAlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram EcosystemSeptember 3, 2025 | globenewswire.comPortage Biotech Reports Results for Fiscal Year Ended March 31, 2025July 25, 2025 | globenewswire.comPortage Biotech Regains Nasdaq Compliance, Maintains Listing On Capital Market | NasdaqJune 27, 2025 | nasdaq.comPRTG Portage Biotech Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comSee More Headlines PRTG Stock Analysis - Frequently Asked Questions How were Portage Biotech's earnings last quarter? Portage Biotech Inc. (NASDAQ:PRTG) announced its quarterly earnings results on Tuesday, November, 26th. The company reported ($1.26) earnings per share (EPS) for the quarter. When did Portage Biotech's stock split? Portage Biotech shares reverse split on the morning of Thursday, August 15th 2024.The 1-20 reverse split was announced on Tuesday, August 13th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Portage Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Portage Biotech investors own include Meta Platforms (META), Alimera Sciences (ALIM), AirMedia Group (ANTE), Broadcom (AVGO), Barnwell Industries (BRN) and Crescent Biopharma (CBIO). Company Calendar Last Earnings11/26/2024Today6/25/2026Fiscal Year End3/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRTG CIK1095435 Webwww.portagebiotech.com Phone416-929-1806FaxN/AEmployees6Year Founded1973Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.02 Quick Ratio2.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.79) per share Price / Book-9.66Miscellaneous Outstanding Shares1,050,000Free Float608,000Market Cap$8.01 million OptionableOptionable Beta0.25 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:PRTG) was last updated on 6/25/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Portage Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Portage Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
